My academic and research interests are focused on anatomic pathology, oncologic pathology, cytopathology, immunohistochemistry, and molecular diagnostics, with particular attention to the translational role of biomarkers in solid tumors. During my training in Anatomic Pathology, I have developed a strong interest in uropathology, thyroid pathology, dermatopathology, gynecologic pathology, soft tissue pathology and melanocytic lesions. My research mainly explores the diagnostic, prognostic, and predictive value of immunohistochemical and molecular markers, including PD-L1, ADAR2, androgen receptor, p16, MTAP, and other emerging biomarkers involved in tumor classification, risk stratification, therapeutic decision-making, and patient follow-up. I am particularly interested in the integration of conventional morphology with ancillary techniques, molecular testing, cytology, and imaging-related data to improve diagnostic accuracy and support precision oncology. In my daily clinical and academic work, I am involved in the gross examination of surgical specimens, histological and cytological diagnosis, immunohistochemical work-up, molecular diagnostic workflows, multidisciplinary tumor boards, and teaching activities. My overall aim is to contribute to a more integrated, clinically oriented, and translational approach to diagnostic pathology, bridging routine practice with biomarker-driven cancer research.
My academic and research interests are focused on anatomic pathology, oncologic pathology, cytopathology, immunohistochemistry, and molecular diagnostics, with particular attention to the translational role of biomarkers in solid tumors. During my training in Anatomic Pathology, I have developed a strong interest in uropathology, thyroid pathology, dermatopathology, gynecologic pathology, soft tissue pathology and melanocytic lesions. My research mainly explores the diagnostic, prognostic, and predictive value of immunohistochemical and molecular markers, including PD-L1, ADAR2, androgen receptor, p16, MTAP, and other emerging biomarkers involved in tumor classification, risk stratification, therapeutic decision-making, and patient follow-up. I am particularly interested in the integration of conventional morphology with ancillary techniques, molecular testing, cytology, and imaging-related data to improve diagnostic accuracy and support precision oncology. In my daily clinical and academic work, I am involved in the gross examination of surgical specimens, histological and cytological diagnosis, immunohistochemical work-up, molecular diagnostic workflows, multidisciplinary tumor boards, and teaching activities. My overall aim is to contribute to a more integrated, clinically oriented, and translational approach to diagnostic pathology, bridging routine practice with biomarker-driven cancer research.